重组人促红细胞生成素治疗新生儿缺氧缺血性脑病的效果分析  

Effect of recombinant human erythropoietin on neonatal hypoxic-ischemic encephalopathy

作　　者：朱萍[1] 李德亮[1] 张伟业 ZHU Ping;LI Deliang;ZHANG Weiye(Nanyang Central Hospital,Nanyang 473000,China)

机构地区：[1]南阳市中心医院,河南南阳473000

出　　处：《中国实用神经疾病杂志》2020年第24期2176-2180,共5页Chinese Journal of Practical Nervous Diseases

摘　　要：目的观察重组人促红细胞生成素治疗新生儿缺氧缺血性脑病的疗效及对患儿生长发育的影响。方法50例新生儿缺氧缺血性脑病患儿随机分为试验组及对照组各25例,2组患儿自出生当日起予以对症支持的常规治疗,在常规治疗基础上,试验组于第3天给予重组人促红细胞生成素400 IU/kg,每周3次,连续4周。治疗后第7天、第14天及第28天分别对2组患儿进行新生儿行为神经测定评分,并于治疗后3个月进行智能发育测试,观察患儿神经行为发育的变化。结果试验组第7天、第14天及第28天的新生儿行为神经测定评分(分别为32.4±1.32、36.3±1.47、37.7±1.81)均明显高于对照组(分别为30.5±1.56、34.8±2.14、36.1±2.03),差异有统计学意义(t=2.885、3.483、2.933,P<0.01)。治疗后3个月试验组智能发育指数(MDI)、运动发育指数(PDI)评分均高于对照组(MDI分别为76%、36%;PDI分别为72%、28%),差异有统计学意义(Z=17.286,P<0.05)。结论重组人促红细胞生成素能提高缺氧缺血性脑病患儿行为神经测定及智能发育测试评分,具有神经保护和恢复作用,对缺氧缺血性脑病患儿的近期治疗效果显著,有利于患儿的远期预后。Objective To observe the curative effect of recombinant human erythropoietine in the treatment of neonatal hypoxic-ischemic encephalopathy and its influence on the growth and development of children.Methods Fifty cases of neonatal hypoxic-ischemic encephalopathy were randomly divided into treatment group(n=25)and control group(n=25).The two groups were given symptomatic and supportive conventional treatment from the day of birth,while the treatment group was given recombinant human erythropoietine 400 IU/kg on the third day,three times a week for four weeks.Neonatal behavioral neurological assessment scores of the two groups were measured on the 7th,14th and 28th day after treatment,and the intellectual development test was conducted at 3 months after treatment to observe the changes of neurobehavioral development.Results The neonatal behavioral neurological assessment scores on the 7th,14th and 28th day of recombinant human erythropoietine treatment group(32.4±1.32,36.3±1.47 and 37.7±1.81,respectively)were significantly higher than those of the control group(30.5±1.56,34.8±2.14 and 36.1±2.03,respectively),and the differences were statistically significant(t value was 2.885,3.483 and 2.933,respectively,all P<0.01).Three months after treatment,the scores of mental development index and psychomotor development index in recombinant human erythropoietine treatment group were higher than those in control group(MDI was 76%and 36%;PDI was 72%and 28%),and the difference was statistically significant(Z value was 17.286,P<0.05).Conclusion Recombinant human erythropoietine can improve the neonatal behavioral neurological assessment and intellectual development test scores of hypoxic-ischemic encephalopathy children,and has neuroprotective and recovery effects.Recombinant human erythropoietine has a significant effect on the short-term treatment of hypoxic-ischemic encephalopathy children,and is conducive to the long-term prognosis of hypoxic-ischemic encephalopathy children.

关 键 词：新生儿缺氧缺血性脑病 重组人促红细胞生成素 神经保护 生长发育 

分 类 号：R722.1[医药卫生—儿科]